the following general definitions are provided to better understand the invention : “ alkyl ” refers to a moiety and as a structural element of other groups , for example halo - substituted - alkyl and alkoxy , and may be straight - chained or branched . an optionally substituted alkyl , alkenyl or alkynyl as used herein may be optionally halogenated ( e . g ., cf 3 ), or may have one or more carbons that is substituted or replaced with a heteroatom , such as nr , o or s ( e . g ., — och 2 ch 2 o —, alkylthiols , thioalkoxy , alkylamines , etc ). “ aryl ” refers to a monocyclic or fused bicyclic aromatic ring containing carbon atoms . “ arylene ” means a divalent radical derived from an aryl group . for example , an aryl group may be phenyl , indenyl , indanyl , naphthyl , or 1 , 2 , 3 , 4 - tetrahydronaphthalenyl , which may be optionally substituted in the ortho , meta or para position . “ heteroaryl ” as used herein is as defined for aryl above , where one or more of the ring members is a heteroatom . examples of heteroaryls include but are not limited to pyridyl , pyrazinyl , indolyl , indazolyl , quinoxalinyl , quinolinyl , benzofuranyl , benzopyranyl , benzothiopyranyl , benzo [ 1 , 3 ] dioxole , imidazolyl , benzo - imidazolyl , pyrimidinyl , furanyl , oxazolyl , isoxazolyl , triazolyl , benzotriazolyl , tetrazolyl , pyrazolyl , thienyl , pyrrolyl , isoquinolinyl , purinyl , thiazolyl , tetrazinyl , benzothiazolyl , oxadiazolyl , benzoxadiazolyl , etc . a “ carbocyclic ring ” as used herein refers to a saturated or partially unsaturated , monocyclic , fused bicyclic or bridged polycyclic ring containing carbon atoms , which may optionally be substituted , for example , with ═ o . examples of carbocyclic rings include but are not limited to cyclopropyl , cyclobutyl , cyclopentyl , cyclohexyl , cyclopropylene , cyclohexanone , etc . a “ heterocyclic ring ” as used herein is as defined for a carbocyclic ring above , wherein one or more ring carbons is a heteroatom . for example , a heterocyclic ring may contain n , o , s , — n ═, — s —, — s ( o ), — s ( o ) 2 —, or — nr — wherein r may be hydrogen , c 1 - 4 alkyl or a protecting group . examples of heterocyclic rings include but are not limited to morpholino , pyrrolidinyl , pyrrolidinyl - 2 - one , piperazinyl , piperidinyl , piperidinylone , 1 , 4 - dioxa - 8 - aza - spiro [ 4 . 5 ] dec - 8 - yl , 1 , 2 , 3 , 4 - tetrahydroquinolinyl , etc . heterocyclic rings as used herein may encompass bicyclic amines and bicyclic diamines . “ salts ” ( which , what is meant by “ or salts thereof ” or “ or a salt thereof ”), can be present alone or in mixture with free compound , e . g . the compound of the formula ( i ), and are preferably pharmaceutically acceptable salts . such salts of the compounds of formula ( i ) are formed , for example , as acid addition salts , preferably with organic or inorganic acids , from compounds of formula ( i ) with a basic nitrogen atom . suitable inorganic acids are , for example , halogen acids , such as hydrochloric acid , sulfuric acid , or phosphoric acid . suitable organic acids are , e . g ., carboxylic acids or sulfonic acids , such as fumaric acid or methansulfonic acid . for isolation or purification purposes it is also possible to use pharmaceutically unacceptable salts , for example picrates or perchlorates . for therapeutic use , only pharmaceutically acceptable salts or free compounds are employed ( where applicable in the form of pharmaceutical preparations ), and these are therefore preferred . in view of the close relationship between the novel compounds in free form and those in the form of their salts , including those salts that can be used as intermediates , for example in the purification or identification of the novel compounds , any reference to the free compounds hereinbefore and hereinafter is to be understood as referring also to the corresponding salts , as appropriate and expedient . the salts of compounds of formula ( i ) are preferably pharmaceutically acceptable salts ; suitable counter - ions forming pharmaceutically acceptable salts are known in the field . “ combination ” refers to either a fixed combination in one dosage unit form , or a non - fixed combination ( or kit of parts ) for the combined administration where a compound of the formula ( i ) and a combination partner ( e . g . another drug as explained below , also referred to as “ therapeutic agent ” or “ co - agent ”) may be administered independently at the same time or separately within time intervals , especially where these time intervals allow that the combination partners show a cooperative , e . g . synergistic effect . the term “ combined administration ” or the like as utilized herein are meant to encompass administration of the selected combination partner to a single subject in need thereof ( e . g . a patient ), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time . the term “ fixed combination ” means that the active ingredients , e . g . a compound of formula ( i ) and a combination partner , are both administered to a patient simultaneously in the form of a single entity or dosage . the terms “ non - fixed combination ” or “ kit of parts ” mean that the active ingredients , e . g . a compound of formula ( i ) and a combination partner , are both administered to a patient as separate entities either simultaneously , concurrently or sequentially with no specific time limits , wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient . the latter also applies to cocktail therapy , e . g . the administration of three or more active ingredients . “ treatment ” includes prophylactic ( preventive ) and therapeutic treatment as well as the delay of progression of a disease or disorder . the term “ prophylactic ” means the prevention of the onset or recurrence of diseases involving proliferative diseases . the term “ delay of progression ” as used herein means administration of the combination to patients being in a pre - stage or in an early phase of the proliferative disease to be treated , in which patients for example a pre - form of the corresponding disease is diagnosed or which patients are in a condition , e . g . during a medical treatment or a condition resulting from an accident , under which it is likely that a corresponding disease will develop . “ subject ” is intended to include animals . examples of subjects include mammals , e . g ., humans , dogs , cows , horses , pigs , sheep , goats , cats , mice , rabbits , rats , and transgenic non - human animals . in certain embodiments , the subject is a human , e . g ., a human suffering from , at risk of suffering from , or potentially capable of suffering from a brain tumor disease . particularly preferred , the subject is human . “ pharmaceutical preparation ” or “ pharmaceutical composition ” refer to a mixture or solution containing at least one therapeutic compound to be administered to a mammal , e . g ., a human in order to prevent , treat or control a particular disease or condition affecting the mammal . “ co - administer ”, “ co - administration ” or “ combined administration ” or the like are meant to encompass administration of the selected therapeutic agents to a single patient , and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time . “ pharmaceutically acceptable ” refers to those compounds , materials , compositions and / or dosage forms , which are , within the scope of sound medical judgment , suitable for contact with the tissues of mammals , especially humans , without excessive toxicity , irritation , allergic response and other problem complications commensurate with a reasonable benefit / risk ratio . “ therapeutically effective ” preferably relates to an amount that is therapeutically or in a broader sense also prophylactically effective against the progression of a proliferative disease . “ single pharmaceutical composition ” refers to a single carrier or vehicle formulated to deliver effective amounts of both therapeutic agents to a patient . the single vehicle is designed to deliver an effective amount of each of the agents , along with any pharmaceutically acceptable carriers or excipients . in some embodiments , the vehicle is a tablet , capsule , pill , or a patch . in other embodiments , the vehicle is a solution or a suspension . “ dose range ” refers to an upper and a lower limit of an acceptable variation of the amount of agent specified . typically , a dose of the agent in any amount within the specified range can be administered to patients undergoing treatment . the terms “ about ” or “ approximately ” usually means within 20 %, more preferably within 10 %, and most preferably still within 5 % of a given value or range . alternatively , especially in biological systems , the term “ about ” means within about a log ( i . e ., an order of magnitude ) preferably within a factor of two of a given value . the present invention relates to a pharmaceutical combination comprising ( a ) a compound of formula ( i ), as defined herein , or a pharmaceutically acceptable salt thereof ; and ( b ) at least one hsp90 inhibitor or a pharmaceutically acceptable salt thereof . such combination may be for simultaneous , separate or sequential use for the treatment of a proliferative disease . ( a ) the geldanamycin derivative , tanespimycin ( 17 - allylamino - 17 - demethoxygeldanamycin )( also known as kos - 953 and 17 - aag ), which is available from sigma - aldrich co , llc ( st . louis , mo . ), and disclosed in u . s . pat . no . 4 , 261 , 989 , dated apr . 14 , 1981 , which is hereby incorporated into the present application by reference , and other geldanamycin - related compounds ; ( b ) radicicol , which is available from sigma - aldrich co , llc ( st . louis , mo . ); ( c ) 6 - chloro - 9 -( 4 - methoxy - 3 , 5 - dimethylpyridin - 2 - ylmethyl )- 9h - purin - 2 - amine methanesulfonate ( also known as cnf2024 )( conforma therapeutics corp . ); ( d ) ipi504 ; ( e ) snx5422 ; ( f ) 5 -( 2 , 4 - dihydroxy - 5 - isopropyl - phenyl )- 4 -( 4 - morpholin - 4 - ylmethyl - phenyl )- isoxazole - 3 - carboxylic acid ethylamide ( auy922 ), which is disclosed in structure and with the process for its manufacture in pct application no . wo04 / 072051 , published on aug . 26 , 2004 , which is hereby incorporated into the present application by reference ; and ( g ) ( r )- 2 - amino - 7 -[ 4 - fluoro - 2 -( 6 - methyoxy - pyridin - 2 - yl )- phenyl ]- 4 - methyl - 7 , 8 - dihydro - 6h - pyrido [ 4 , 3 - d ] pyrimidin - 5 - one ( hsp990 ), which is disclosed in structure and with the process for its manufacture in u . s . patent application publication no . 2007 - 0123546 , published on may 31 , 2007 , which is hereby incorporated into the present application by reference ; preferred hsp90 inhibitors for the present invention are 5 -( 2 , 4 - dihydroxy - 5 - isopropyl - phenyl )- 4 -( 4 - morpholin - 4 - ylmethyl - phenyl )- isoxazole - 3 - carboxylic acid ethylamide ( auy922 ) and ( r )- 2 - amino - 7 -[ 4 - fluoro - 2 -( 6 - methyoxy - pyridin - 2 - yl )- phenyl ]- 4 - methyl - 7 , 8 - dihydro - 6h - pyrido [ 4 , 3 - d ] pyrimidin - 5 - one ( hsp990 ) or pharmaceutically acceptable salts thereof . comprised are likewise the pharmaceutically acceptable salts thereof , the corresponding racemates , diastereoisomers , enantiomers , tautomers , as well as the corresponding crystal modifications of above disclosed compounds where present , e . g . solvates , hydrates and polymorphs , which are disclosed therein . the compounds used as active ingredients in the combinations of the present invention can be prepared and administered as described in the cited documents , respectively . also within the scope of this invention is the combination of more than two separate active ingredients as set forth above , i . e ., a pharmaceutical combination within the scope of this invention could include three active ingredients or more . in one embodiment of the present invention , the pharmaceutical combination comprises the compound of formula ( i ) that is or a pharmaceutically acceptable salt thereof , and at least one hsp90 inhibitor selected from 5 -( 2 , 4 - dihydroxy - 5 - isopropyl - phenyl )- 4 -( 4 - morpholin - 4 - ylmethyl - phenyl )- isoxazole - 3 - carboxylic acid ethylamide ( auy922 ), ( r )- 2 - amino - 7 -[ 4 - fluoro - 2 -( 6 - methyoxy - pyridin - 2 - yl )- phenyl ]- 4 - methyl - 7 , 8 - dihydro - 6h - pyrido [ 4 , 3 - d ] pyrimidin - 5 - one ( hsp990 ), or pharmaceutically acceptable salts thereof . in one embodiment of the present invention , the pharmaceutical combination comprises the compound of formula ( i ) that is 5 - chloro - n2 -( 2 - isopropoxy - 5 - methyl - 4 -( piperidin - 4 - yl ) phenyl )- n4 -[ 2 -( propane - 2 - sulfonyl )- phenyl ]- pyrimidine - 2 , 4 - diamine or pharmaceutically acceptable salts thereof , and at least one hsp90 inhibitor 5 -( 2 , 4 - dihydroxy - 5 - isopropyl - phenyl )- 4 -( 4 - morpholin - 4 - ylmethyl - phenyl )- isoxazole - 3 - carboxylic acid ethylamide ( auy922 ) or a pharmaceutically acceptable salt thereof . in one embodiment of the present invention , the pharmaceutical combination comprises the compound of formula ( i ) that is 5 - chloro - n2 -( 2 - isopropoxy - 5 - methyl - 4 -( piperidin - 4 - yl ) phenyl )- n4 -[ 2 -( propane - 2 - sulfonyl )- phenyl ]- pyrimidine - 2 , 4 - diamine ( compound a ) having the following structure or pharmaceutically acceptable salts thereof and the hsp inhibitor is 5 -( 2 , 4 - dihydroxy - 5 - isopropyl - phenyl )- 4 -( 4 - morpholin - 4 - ylmethyl - phenyl )- isoxazole - 3 - carboxylic acid ethylamide ( auy922 ). in a further embodiment , the compound of formula ( i ) is 5 - chloro - n2 -( 2 - isopropoxy - 5 - methyl - 4 -( piperidin - 4 - yl ) phenyl )- n4 -[ 2 -( propane - 2 - sulfonyl )- phenyl ]- pyrimidine - 2 , 4 - diamine ( compound a ) and the hsp inhibitor is 5 -( 2 , 4 - dihydroxy - 5 - isopropyl - phenyl )- 4 -( 4 - morpholin - 4 - ylmethyl - phenyl )- isoxazole - 3 - carboxylic acid ethylamide ( auy922 ). it has now been surprisingly found that the combination of a compound of formula ( i ), and at least one hsp90 inhibitor possess beneficial therapeutic properties , which render it particularly useful for the treatment of proliferative diseases , particularly cancer . in one aspect , the present invention provides a pharmaceutical combination comprising ( a ) a compound of formula ( i ), and ( b ) at least one hsp90 inhibitor or a pharmaceutically acceptable salt thereof , for use in the treatment of a proliferative disease , particularly cancer . in one aspect , the present invention provides the use of a pharmaceutical combination comprising a compound of formula ( i ) or a pharmaceutically acceptable salt thereof and at least one hsp90 inhibitor or a pharmaceutically acceptable salt thereof , for the preparation of a medicament for the treatment of a proliferative disease . in one aspect , the present invention further relates to a method for treating a proliferative disease in a subject in need thereof , comprising administering to said subject a therapeutically effective amount of a compound of formula ( i ) or a pharmaceutically acceptable salt thereof , and at least one hsp90 inhibitor or a pharmaceutically acceptable salt thereof . in accordance with the present invention , the compound of formula ( i ) and the hsp90 inhibitor may be administered either as a single pharmaceutical composition , as separate compositions , or sequentially . preferably , the present invention is useful for the treating a mammal , especially humans , suffering from a proliferative disease such as cancer . to demonstrate that the combination of a compound of formula ( i ) and at least one hsp90 inhibitor is particularly suitable for the effective treatment of proliferative diseases with good therapeutic margin and other advantages , clinical trials can be carried out in a manner known to the skilled person . suitable clinical studies are , e . g ., open label , dose escalation studies in patients with proliferative diseases . such studies prove in particular the synergism of the active ingredients of the combination of the invention . the beneficial effects can be determined directly through the results of these studies which are known as such to a person skilled in the art . such studies are , in particular , suitable to compare the effects of a monotherapy using the active ingredients and a combination of the invention . preferably , the dose of agent ( a ) is escalated until the maximum tolerated dosage is reached , and agent ( b ) is administered with a fixed dose . alternatively , the agent ( a ) is administered in a fixed dose and the dose of agent ( b ) is escalated . each patient receives doses of the agent ( a ) either daily or intermittent . the efficacy of the treatment can be determined in such studies , e . g ., after 12 , 18 or 24 weeks by evaluation of symptom scores every 6 weeks . the administration of a pharmaceutical combination of the invention results not only in a beneficial effect , e . g ., a synergistic therapeutic effect , e . g ., with regard to alleviating , delaying progression of or inhibiting the symptoms , but also in further surprising beneficial effects , e . g ., fewer side effects , an improved quality of life or a decreased morbidity , compared with a monotherapy applying only one of agents ( a ) or agents ( b ) used in the combination of the invention . a further benefit is that lower doses of the active ingredients of the combination of the invention can be used , e . g ., that the dosages need not only often be smaller but are also applied less frequently , which may diminish the incidence or severity of side effects . this is in accordance with the desires and requirements of the patients to be treated . it is one objective of this invention to provide a pharmaceutical composition comprising a quantity , which is jointly therapeutically effective at targeting or preventing proliferative diseases , of each combination partner agent ( a ) and ( b ) of the invention . in one aspect , the present invention relates to a pharmaceutical composition comprising a compound of formula ( i ) or a pharmaceutically acceptable salt thereof and at least one hsp90 inhibitor or a pharmaceutically acceptable salt thereof . in one embodiment , such pharmaceutical composition of the present invention is for use in the treatment of a proliferative disease . in accordance with the present invention , agent ( a ) and agent ( b ) may be administered together in a single pharmaceutical composition , separately in one combined unit dosage form or in two separate unit dosage forms , or sequentially . the unit dosage form may also be a fixed combination . the pharmaceutical compositions for separate administration of agent ( a ) and agent ( b ) or for the administration in a fixed combination ( i . e ., a single galenical composition comprising at least two combination partners ( a ) and ( b )) according to the invention may be prepared in a manner known per se and are those suitable for enteral , such as oral or rectal , topical , and parenteral administration to subjects , including mammals ( warm - blooded animals ) such as humans , comprising a therapeutically effective amount of at least one pharmacologically active combination partner alone , e . g ., as indicated above , or in combination with one or more pharmaceutically acceptable carriers or diluents , especially suitable for enteral or parenteral application . suitable pharmaceutical compositions contain , e . g ., from about 0 . 1 % to about 99 . 9 %, preferably from about 1 % to about 60 %, of the active ingredient ( s ). pharmaceutical compositions for the combination therapy for enteral or parenteral administration are , e . g ., those in unit dosage forms , such as sugar - coated tablets , tablets , capsules or suppositories , ampoules , injectable solutions or injectable suspensions . topical administration is e . g . to the skin or the eye , e . g . in the form of lotions , gels , ointments or creams , or in a nasal or a suppository form . if not indicated otherwise , these are prepared in a manner known per se , e . g ., by means of conventional mixing , granulating , sugar - coating , dissolving or lyophilizing processes . it will be appreciated that the unit content of agent ( a ) or agent ( b ) contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount can be reached by administration of a plurality of dosage units . pharmaceutical compositions may comprise one or more pharmaceutical acceptable carriers or diluents and may be manufactured in conventional manner by mixing one or both combination partners with a pharmaceutically acceptable carrier or diluent . examples of pharmaceutically acceptable diluents include , but are not limited to , lactose , dextrose , mannitol , and / or glycerol , and / or lubricants and / or polyethylene glycol . examples of pharmaceutically acceptable binders include , but are not limited to , magnesium aluminum silicate , starches , such as corn , wheat or rice starch , gelatin , methylcellulose , sodium carboxymethylcellulose and / or polyvinylpyrrolidone , and , if desired , pharmaceutically acceptable disintegrators include , but are not limited to , starches , agar , alginic acid or a salt thereof , such as sodium alginate , and / or effervescent mixtures , or adsorbents , dyes , flavorings and sweeteners . it is also possible to use the compounds of the present invention in the form of parenterally administrable compositions or in the form of infusion solutions . the pharmaceutical compositions may be sterilized and / or may comprise excipients , for example preservatives , stabilizers , wetting compounds and / or emulsifiers , solubilisers , salts for regulating the osmotic pressure and / or buffers . in particular , a therapeutically effective amount of each of the combination partner of the combination of the invention may be administered simultaneously or sequentially and in any order , and the components may be administered separately or as a fixed combination . for example , the method of preventing or treating proliferative diseases according to the invention may comprise : ( i ) administration of the first agent ( a ) in free or pharmaceutically acceptable salt form ; and ( ii ) administration of an agent ( b ) in free or pharmaceutically acceptable salt form , simultaneously or sequentially in any order , in jointly therapeutically effective amounts , preferably in synergistically effective amounts , e . g ., in daily or intermittently dosages corresponding to the amounts described herein . the individual combination partners of the combination of the invention may be administered separately at different times during the course of therapy or concurrently in divided or single combination forms . furthermore , the term administering also encompasses the use of a pro - drug of a combination partner that convert in vivo to the combination partner as such . the instant invention is therefore to be understood as embracing all such regimens of simultaneous or alternating treatment and the term “ administering ” is to be interpreted accordingly . the effective dosage of each of combination partner agent ( a ) or agent ( b ) employed in the combination of the invention may vary depending on the particular compound or pharmaceutical composition employed , the mode of administration , the condition being treated , the severity of the condition being treated . thus , the dosage regimen of the combination of the invention is selected in accordance with a variety of factors including type , species , age , weight , sex and medical condition of the patient ; the severity of the condition to be treated ; the route of administration ; the renal and hepatic function of the patient ; and the particular compound employed . a physician , clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent , counter or arrest the progress of the condition . optimal precision in achieving concentration of drug within the range that yields efficacy requires a regimen based on the kinetics of the drug &# 39 ; s availability to target sites . this involves a consideration of the distribution , equilibrium , and elimination of a drug . for purposes of the present invention , a therapeutically effective dose will generally be a total daily dose administered to a host in single or divided doses . the compound of formula ( i ) may be administered to a host in a daily dosage range of , for example , from about 0 . 05 to about 50 mg / kg body weight of the recipient , preferably about 0 . 1 - 25 mg / kg body weight of the recipient , more preferably from about 0 . 5 to 10 mg / kg body weight of the recipient . agent ( b ) may be administered to a host in a daily dosage range of , for example , from about 0 . 001 to 1000 mg / kg body weight of the recipient , preferably from 1 . 0 to 100 mg / kg body weight of the recipient , and most preferably from 1 . 0 to 50 mg / kg body weight of the recipient . dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose . a further benefit is that lower doses of the active ingredients of the combination of the invention can be used , e . g ., that the dosages need not only often be smaller but are also applied less frequently , or can be used in order to diminish the incidence of side effects . this is in accordance with the desires and requirements of the patients to be treated . the combination of the compound of formula ( i ) and an hsp90 inhibitor can be used alone or combined with at least one other pharmaceutically active compound for use in these pathologies . these active compounds can be combined in the same pharmaceutical preparation or in the form of combined preparations “ kit of parts ” in the sense that the combination partners can be dosed independently or by use of different fixed combinations with distinguished amounts of the combination partners , i . e ., simultaneously or at different time points . the parts of the kit of parts can then , e . g ., be administered simultaneously or chronologically staggered , that is at different time points and with equal or different time intervals for any part of the kit of parts . non - limiting examples of compounds which can be cited for use in combination with the combination of a compound of formula ( i ) and at least one hsp90 inhibitor are cytotoxic chemotherapy drugs , such as anastrozole , doxorubicin hydrochloride , flutamide , dexamethaxone , docetaxel , cisplatin , paclitaxel , etc . further , the combination of a pyrimidylaminobenzamide compound and an hsp90 inhibitor could be combined with other inhibitors of signal transduction or other oncogene - targeted drugs with the expectation that significant synergy would result . the combination of the present invention is particularly useful for the treatment of proliferative diseases . the term “ proliferative disease ” includes , but not restricted to , cancer , tumor , hyperplasia , restenosis , cardiac hypertrophy , immune disorder and inflammation . examples for a proliferative disease the can be treated with the combination of the present invention are for instance cancers , including , for example , sarcoma ; lung ; bronchus ; prostate ; breast ( including sporadic breast cancers and sufferers of cowden disease ); pancreas ; gastrointestinal cancer or gastric ; colon ; rectum ; colorectal adenoma ; thyroid ; liver ; intrahepatic bile duct ; hepatocellular ; adrenal gland ; stomach ; glioma ; glioblastoma ; endometrial ; kidney ; renal pelvis ; urinary bladder ; uterine corpus ; uterine cervix ; vagina ; ovary ; multiple myeloma ; esophagus ; a leukaemia ; acute myelogenous leukemia ; chronic myelogenous leukemia ; lymphocytic leukemia ; myeloid leukemia ; brain ; oral cavity and pharynx ; larynx ; small intestine ; non - hodgkin lymphoma ; melanoma ; villous colon adenoma ; a neoplasia ; a neoplasia of epithelial character ; lymphomas ; a mammary carcinoma ; basal cell carcinoma ; squamous cell carcinoma ; actinic keratosis ; a tumor of the neck or head ; polycythemia vera ; essential thrombocythemia ; myelofibrosis with myeloid metaplasia ; and walden stroem disease . further examples include , polycythemia vera , essential thrombocythemia , myelofibrosis with myeloid metaplasia , asthma , copd , ards , loffler &# 39 ; s syndrome , eosinophilic pneumonia , parasitic ( in particular metazoan ) infestation ( including tropical eosinophilia ), bronchopulmonary aspergillosis , polyarteritis nodosa ( including churg - strauss syndrome ), eosinophilic granuloma , eosinophil - related disorders affecting the airways occasioned by drug - reaction , psoriasis , contact dermatitis , atopic dermatitis , alopecia areata , erythema multiforme , dermatitis herpetiformis , scleroderma , vitiligo , hypersensitivity angiitis , urticaria , bullous pemphigoid , lupus erythematosus , pemphisus , epidermolysis bullosa acquisita , autoimmune haematogical disorders ( e . g . haemolytic anaemia , aplastic anaemia , pure red cell anaemia and idiopathic thrombocytopenia ), systemic lupus erythematosus , polychondritis , scleroderma , wegener granulomatosis , dermatomyositis , chronic active hepatitis , myasthenia gravis , steven - johnson syndrome , idiopathic sprue , autoimmune inflammatory bowel disease ( e . g . ulcerative colitis and crohn &# 39 ; s disease ), endocrine opthalmopathy , grave &# 39 ; s disease , sarcoidosis , alveolitis , chronic hypersensitivity pneumonitis , multiple sclerosis , primary biliary cirrhosis , uveitis ( anterior and posterior ), interstitial lung fibrosis , psoriatic arthritis , glomerulonephritis , cardiovascular diseases , atherosclerosis , hypertension , deep venous thrombosis , stroke , myocardial infarction , unstable angina , thromboembolism , pulmonary embolism , thrombolytic diseases , acute arterial ischemia , peripheral thrombotic occlusions , and coronary artery disease , reperfusion injuries , retinopathy , such as diabetic retinopathy or hyperbaric oxygen - induced retinopathy , and conditions characterized by elevated intraocular pressure or secretion of ocular aqueous humor , such as glaucoma . in one embodiment , the proliferative disease treated by the combination of the present invention is a cancer that can be beneficially treated by the inhibition of hsp90 and / or alk including , for example , gastric , lung and bronchus ; prostate ; breast ; pancreas ; colon ; rectum ; thyroid ; liver and intrahepatic bile duct ; kidney and renal pelvis ; urinary bladder ; uterine corpus ; uterine cervix ; ovary ; multiple myeloma ; esophagus ; acute myelogenous leukemia ; chronic myelogenous leukemia ; lymphocytic leukemia ; myeloid leukemia ; brain ; oral cavity and pharynx ; larynx ; small intestine ; non - hodgkin lymphoma ; melanoma ; and villous colon adenoma . in one embodiment , the proliferative disease treated by the combination of the present invention is a cancer of the esophagus , gastrointestinal cancer or gastric . where a tumor , a tumor disease , sarcoma , a carcinoma or a cancer are mentioned , also metastasis in the original organ or tissue and / or in any other location are implied alternatively or in addition , whatever the location of the tumor and / or metastasis . the combination of the present invention is particularly useful for the treatment of proliferative diseases , particularly cancers and other malignancies , mediated by anaplastic lymphoma kinase ( alk ). proliferative diseases may include those showing overexpression or amplification of alk , including lymphoma , osteosarcoma , melanoma , or a tumor of breast , renal , prostate , colorectal , thyroid , ovarian , pancreatic , neuronal , lung ( non - small cell lung cancer and small cell lung cancer ), uterine or gastrointestinal tumor , cancer of the bowel ( colon and rectum ), stomach cancer , cancer of liver , melanoma , bladder tumor , and cancer of head and neck . hematological and neoplastic diseases , for example in anaplastic large - cell lymphoma ( alcl ) and non - hodgkin &# 39 ; s lymphomas ( nhl ), specifically in alk + nhl or alkomas in inflammatory myofibroblastic tumors ( imt ) and neuroblastomas . in one embodiment , the present invention relates to a method for treating a proliferative disorder comprising administering to said subject a therapeutically effective amount of a compound of formula ( i ) and at least one hsp90 inhibitor selected from the geldanamycin derivative , tanespimycin ( 17 - allylamino - 17 - demethoxygeldanamycin ) ( also known as kos - 953 and 17 - aag ); radicicol ; 6 - chloro - 9 -( 4 - methoxy - 3 , 5 - dimethylpyridin - 2 - ylmethyl )- 9h - purin - 2 - amine methanesulfonate ( also known as cnf2024 ); ipi504 ; snx5422 ; 5 -( 2 , 4 - dihydroxy - 5 - isopropyl - phenyl )- 4 -( 4 - morpholin - 4 - ylmethyl - phenyl )- isoxazole - 3 - carboxylic acid ethylamide ( auy922 ); and ( r )- 2 - amino - 7 -[ 4 - fluoro - 2 -( 6 - methyoxy - pyridin - 2 - yl )- phenyl ]- 4 - methyl - 7 , 8 - dihydro - 6h - pyrido [ 4 , 3 - d ] pyrimidin - 5 - one ( hsp990 ) or a pharmaceutically acceptable salt thereof . the present invention further relates to a kit comprising a compound of formula ( i ), or a pharmaceutically acceptable salt thereof , and at least one hsp90 inhibitor or a pharmaceutically acceptable salt thereof , and a package insert or other labeling including directions for treating a proliferative disease . the present invention further relates to a kit comprising a compound of formula ( i ), or a pharmaceutically acceptable salt thereof , and a package insert or other labeling including directions for treating a proliferative disease by co - administering at least one hsp90 inhibitor or a pharmaceutically acceptable salt thereof . antitumor effect of 5 -{ 2 , 4 - dihydroxy - 5 - isopropyl - phersys )- 4 -{ 4 - morpholin - 4 - ylmethyl - phenyl )˜ isoxazole - 3 - carboxylic acid ethylamide ( auy922 ) and 5 - chloro - n2 -( 2 - isopropoxy - 5 - methyl - 4 -( piperidin - 4 - yl ) phenyl )- n4 -[ 2 -( propane - 2 - sulfonyl )- phenyl ]- pyrimidine - 2 , 4 - diamine ( compound a ) in the human lung primary tumor xenograft model hlux1787 the subcutaneous human lung primary tumor xenograft model hlux1787 harbors an eml4 - alk variant 2 translocation and has high levels of phospho - cmet . the primary tumor sample hlux - 1787 is a human primary tumor xenograft that is obtained from oncology research at novartis institute for biomedical research at cambridge , mass . the xenograft model was established by direct subcutaneous ( sc ) implantation of minced surgical material into the subcutaneous area of nude adult female mice . the tumors were then serially passaged in mice to enable studies in this report . hlux - 1787 primary tumors were harvested and cut into 3 × 3 × 3 mm 3 size and implanted into nude mice . the tumors reached approximately 200 mm 3 at 24 - 27 days post implantation . on day 24 ( trp - 0318 ) or day 27 ( trp - 0335 ), tumors were measured and mice were randomized into treatment groups based on tumor volume . compound a was dissolved in 0 . 5 % mc / 0 . 5 % tween 80 . it is stable for at least one week at room temperature . the dosing volume was 10 ml / kg . auy922 ( mesylate salt ) was dissolved in 5 % dextrose in water ( d5w ), and prepared fresh before dosing . it was administered at 60 . 5 mg / kg ( equivalent to 50 mg / kg free base ), iv , twice a week ( 2qw ) or once a week ( qw ). the designs for study trp0318 and trp0335 are summarized in tables 1 - 1 and 1 - 2 . treatment dose was body weight adjusted . tumor dimensions and body weights were collected at the time of randomization and twice weekly thereafter for the study duration . the following data were provided after each day of data collection : incidence of mortality , individual and group average body weight , and individual and group average tumor volume . table 1 - 1 dose and schedule for study trp0318 number treatment dose schedule of mice d5w 5 ml / kg 2qw iv 4 0 . 5 % mc / 10 ml / kg qd po 0 . 5 % tween 80 compound a 10 mg / kg qd , po 4 auy922 50 mg / kg 2qw , iv 4 compound a 10 mg / kg qd , po 4 auy922 50 mg / kg 2qw , iv for study trp0318 , treatments were initiated on day 27 following tumor fragment implantation , when the average tumor volume was 240 mm 3 . treatments continued for 20 days . for study trp0335 , treatments were initiated on day 24 following tumor fragment implantation , when the average tumor volume was 240 mm 3 . treatments continued for 13 days . the % change in body weight was calculated as ( bw current − bw initial )/( bw initial )× 100 %. data is presented as percent body weight change from the day of treatment initiation . t = mean tumor volume of the drug - treated group on the final day of the study ; δt = mean tumor volume of the drug - treated group on the final day of the study — mean tumor volume of the drug - treated group on initial day of dosing ; t initial = mean tumor volume of the drug - treated group on initial day of dosing ; c = mean tumor volume of the control group on the final day of the study ; and δc = mean tumor volume of the control group on the final day of the study — mean tumor volume of the control group on initial day of dosing . tumor volume and percent body weight change were expressed as mean ± standard error of the mean ( sem ). plasma concentration of compound was expressed as mean ± standard deviation . delta tumor volume was used for statistical analysis . between group comparisons were carried out using the one way analysis of variance ( anova ) followed by a post hoc tukey test . for all statistical evaluations , the level of significance was set at p & lt ; 0 . 05 . significance compared to the vehicle control group is reported unless otherwise stated . the initial mean body weight and percentage of body weight change at termination are summarized in table 1 - 3 and shown in fig1 and 2 ( trp - 0318 ), and summarized in table 1 - 4 ( trp - 0335 ) and shown in fig3 and 4 . in trp - 0318 , compound a was well tolerated at 10 mg / kg , with percent body weight change as 3 . 5 %. the percent body weight change for the vehicle - treated group was 4 . 1 % and the auy922 50 mg / kg treated group was − 6 . 8 %. compound a at 10 mg / kg in combination of auy922 at 50 mg / kg twice a week resulted in − 5 . 2 % body weight losses . similarly , in trp - 0335 , compound a was well tolerated at 25 mg / kg with 3 . 0 % body weight change , compared to vehicle - treated group with 1 . 5 % body weight change , and auy922 50 mg / kg once a week and twice a week treated group exhibit 5 . 0 % and − 2 . 2 % body weight changes respectively . compound a at 25 mg / kg in combination with auy922 at 50 mg / kg once a week or auy922 at 50 mg / kg twice a week , were also tolerated well with mean body weight change at 1 . 1 % and − 0 . 1 % respectively . tumor growth and percent t / c are summarized in table 1 - 5 ( trp - 0318 ) and table 1 - 6 ( trp - 0335 ) and illustrated in fig1 and 2 ( trp - 0318 ) to fig3 and 4 ( trp - 0335 ). * p & lt ; 0 . 05 compared to vehicle by one way anova post hoc tukey test . * p & lt ; 0 . 05 compared to vehicle by one way anova post hoc tukey test . ** p & lt ; 0 . 001 compared to vehicle by one way anova post hoc tukey test . in trp - 0318 , compound a at 10 mg / kg produced statistically non - significant anti - tumor effects with t / c 50 . 9 %. auy922 at 50 mg / kg resulted in t / c 19 . 2 % ( p & lt ; 0 . 05 vs vehicle treated group ), compound a at 10 mg / kg in combination of auy922 at 50 mg / kg twice a week resulted in tumor stasis with t / t0 − 6 . 8 % ( p & lt ; 0 . 05 vs vehicle treated group ) ( see table 1 - 5 , fig1 ). in trp - 0335 , compound a at 25 mg / kg resulted in statistically non - significant effects with t / c 45 . 3 %. auy922 at 50 mg / kg once a week and twice a week resulted in t / c 19 . 3 % and 20 . 0 %, respectively ( p & lt ; 0 . 05 vs vehicle treated group ). compound a at 25 mg / kg in combination of auy922 at 50 mg / kg once a week resulted in t / c 16 . 0 % ( p & lt ; 0 . 05 vs vehicle treated group ); compound a at 25 mg / kg in combination of auy922 at 50 mg / kg twice a week resulted in tumor regression with t / t0 − 34 % ( p & lt ; 0 . 001 vs vehicle - treated group ) ( see table 1 - 6 , fig3 ). in the hlux1787 model , compound a at 10 mg / kg and 25 mg / kg yielded 50 . 9 % t / c and 45 . 3 % t / c respectively ; auy922 at 50 mg / kg ( free base ) twice weekly resulted in 20 % t / c ; combinations of compound a at 10 mg / kg or 25 mg / kg with auy922 at 50 mg / kg resulted in tumor stasis ( t / t0 : − 6 . 8 %) and tumor regression ( t / t0 : − 34 %) respectively . increased antitumor effect was observed in the hlux - 1787 model when compound a and the hsp90 inhibitor auy922 were combined . the combination of compound a with auy922 is more potent than either single agent in a lung cancer model which harbors eml4 - alk variant 2 translocation . antitumor effect of 5 -{ 2 , 4 - dihydroxy - 5 - isopropyl - phersys )- 4 -{ 4 - morpholin - 4 - ylmethyl - phenyl )˜ isoxazole - 3 - carboxylic acid ethylamide ( auy922 ) and 5 - chloro - n2 -( 2 - isopropoxy - 5 - methyl - 4 -( piperidin - 4 - yl ) phenyl )- n4 -[ 2 -( propane - 2 - sulfonyl )- phenyl ]- pyrimidine - 2 , 4 - diamine ( compound a ) in the human lung primary tumor xenograft model luf1656 the subcutaneous human lung primary tumor xenograft model luf1656 harbors an eml4 - alk variant 1 translocation and has high levels of egfr expression . egfr , cmet and other rtk signaling pathways are also likely to be activated in these models . tumor fragments from stock mice inoculated with selected primary human lung cancer ( luf1656 ) were harvested and used for inoculation into nu / nu mice . each mouse was inoculated subcutaneously at the right flank with one tumor fragment ( 3 × 3 × 3 mm 3 ) for tumor development . the treatments were started when mean tumor size reached approximately 140 mm 3 ( range 86 . 8 - 245 mm 3 ). the test articles administration and the animal numbers in each group are shown in the experiment design table 2 - 1 . the major endpoint was to see if the tumor growth can be delayed or tumor bearing mice can be cured . tumor size was measured twice weekly in two dimensions using a caliper , and the volume was expressed in mm 3 using the formula : v = 0 . 5a × b 2 where a and b are the long and short diameters of the tumor , respectively . the tumor size was then used for calculations of both t - c and t / c values . t - c was calculated with t as the time ( in days ) required for the mean tumor size of the treatment group to reach a predetermined size ( e . g ., 400 mm 3 ), and c was the time ( in days ) for the mean tumor size of the control group to reach the same size . percent treatment / control ( t / c ) values were calculated using the following formula : t = mean tumor volume of the drug - treated group on the final day of the study ; δt = mean tumor volume of the drug - treated group on the final day of the study — mean tumor volume of the drug - treated group on initial day of dosing ; t initiai = mean tumor volume of the drug - treated group on initial day of dosing ; c = mean tumor volume of the control group on the final day of the study ; and δc = mean tumor volume of the control group on the final day of the study — mean tumor volume of the control group on initial day of dosing . summary statistics , including mean and the standard error of the mean ( sem ), are provided for the tumor volume of each group at each time point . statistical analysis of difference in tumor volume among the groups was conducted using a one - way anova followed by multiple comparisons using tukey hsd . log transformation was performed for homogeneity of variances when necessary . all data were analyzed using spss ( statistical package for the social sciences or statistical product and service solutions ) 16 . 0 . p & lt ; 0 . 05 was considered to be statistically significant . the standard protocols used in pharmacology studies are not pre - powered to demonstrate statistically significant superiority of a combination over the respective single agent treatment . the statistical power is often limited by potent single agent response and / or model variability . the p - values for combination vs single agent treatments are , however , provided . the results of the body weight changes in the tumor bearing mice are shown in fig5 and fig6 . the tumor sizes of the different groups at different time points are shown in table 2 - 3 and table 2 - 4 . tumor sizes in the different treatment groups ( treatment phase , n = 8 ) * p & lt ; 0 . 05 , ** p & lt ; 0 . 01 , *** p & lt ; 0 . 001 , compared with the vehicle control . tumor sizes in the different treatment groups ( re - growth phase , n = 4 ) antitumor activity of compound a as a single agent and in the tumor growth curves of different groups are shown in fig7 and 8 . in this efficacy study , the therapeutic efficacy of compound a as a single agent and in combination with auy922 in the treatment of subcutaneous primary human lung cancer luf1656 xenograft model in nu / nu mice was evaluated . the results of tumor size in different groups at different time points after treatment are shown in the tables 2 - 3 and 2 - 4 and in fig7 and 8 . treatment with compound a as a single agent at 25 mg / kg ( po , qd × 22 days ) showed moderate antitumor activity ( t / c value = 35 . 1 % on day 21 after treatment ) ( p & gt ; 0 . 05 when compared to vehicle ). treatment with compound a as a single agent at 50 and 100 mg / kg ( po , qd × 22 days ) exhibited significant antitumor activity from day 11 to day 21 and day 7 to day 21 after treatment compared with vehicle control ( t / c value = 10 . 9 %, p & lt ; 0 . 01 , at day 21 after treatment of 50 mg / kg compound a treatment group ; and t / c value = 1 . 9 %, p & lt ; 0 . 001 , at day 21 after treatment of 100 mg / kg compound a treatment group ). treatment with auy922 as a single agent at 50 mg / kg ( iv , 2qw × 3 wks ) showed moderate antitumor activity ( t / c value = 38 . 7 % at day 21 after treatment when compared to vehicle ). treatment with 25 mg / kg compound a ( po , qd × 22 days ) plus 50 mg / kg auy922 ( iv , 2qw × 3 wks ) showed significant antitumor activity from day 7 to day 21 after treatment when compared to vehicle control ( t / c value = 11 . 4 %, p & lt ; 0 . 01 , at day 21 after treatment ). the antitumor activity of the combination treatment ( 25 mg / kg compound a + 50 mg / kg auy922 ) was better than that of each monotherapy . based on the body weight data as shown in fig5 and 6 , the test articles compound a at dose levels of 25 , 50 and 100 mg / kg , auy922 at 50 mg / kg and combination of 25 mg / kg compound a with 50 mg / kg auy922 were all tolerated by the primary human lung cancer luf1656 tumor - bearing mice in this study . in summary , the test article compound a at 50 and 100 mg / kg as single agent and 25 mg / kg compound a in combination with 50 mg / kg auy922 all demonstrated statistically significant antitumor activity against the primary human lung cancer luf1656 xenograft model . combination of compound a and auy922 produced increased anti - tumor activity compared to the corresponding monotherapies .
a pharmaceutical combination comprising a compound of formula , or pharmaceutically acceptable salts thereof ; and one or more at least one compound targeting , decreasing or inhibiting the intrinsic atpase activity of hsp90 and / or degrading , targeting , decreasing or inhibiting the hsp90 client proteins via the ubiquitin proteosome pathway ; the uses of such combination in the treatment or prevention of proliferative diseases ; and methods of treating a subject suffering from a proliferative disease ; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination .